Drug intelligence / Profile preview

BRX011

Development stage: Phase 2
Lead developer: BioJiva
Modality: Small Molecules
Administration: Oral

Overview

BRX011 is an investigational oral small molecule inhibitor of Complement Factor D, developed by BioJiva for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Complement Factor D is a serine protease that serves as the rate-limiting enzyme in the activation of the alternative complement pathway, a system whose overactivation is linked to the progression of retinal degeneration in GA. By inhibiting Factor D, BRX011 aims to reduce complement-mediated inflammation and tissue damage in the macula. As an oral therapy, it offers a potentially less invasive alternative to the currently approved intravitreal injections for GA. It is currently being evaluated in Phase 1/2 clinical trials.

Other names: BRX011BRX-011BRX 011

Targets

CFD (Complement Factor D)

Beyond the preview

Go deeper on BRX011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRX011.

Explore the full profile